| Autor: |
Ian M. McElree, Ryan L. Steinberg, Alex C. Martin, Jordan Richards, Sarah L. Mott, Paul T. Gellhaus, Kenneth G. Nepple, Michael A. O'Donnell, Vignesh T. Packiam |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
The Journal of urology. 208(3) |
| ISSN: |
1527-3792 |
| Popis: |
Bacillus Calmette-Guérin (BCG) is currently recommended as adjuvant therapy following complete transurethral resection of bladder tumor for high-risk nonmuscle-invasive bladder cancer (NMIBC). In response to the BCG shortage, gemcitabine plus docetaxel (Gem/Doce) has been utilized at our institution in the BCG-naïve setting. We report the outcomes of patients with high-risk BCG-naïve NMIBC treated with Gem/Doce.We retrospectively reviewed patients with BCG-naïve high-risk NMIBC treated with Gem/Doce from May 2013 through April 2021. Patients received 6 weekly intravesical instillations of sequential 1 gm gemcitabine and 37.5 mg docetaxel after complete transurethral resection of bladder tumor. Monthly maintenance of 2 years was initiated if disease-free at first followup. The primary outcome was recurrence-free survival. Survival was assessed with the Kaplan-Meier method, indexed from the first Gem/Doce instillation. Adverse events were reported using CTCAE (Common Terminology Criteria for Adverse Events) v5 (National Cancer Institute, Bethesda, Maryland). Differences were assessed with the log-rank test.There were 107 patients with a median followup of 15 months included in the analysis. Patients had high-risk characteristics including 47 with any carcinomaGem/Doce is an effective and well-tolerated therapy for BCG-naïve NMIBC. Further investigation is warranted. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
